J INTS BIO Co., Ltd.

Based in South Korea, J INTS BIO Co. , Ltd. is a biotechnology firm focused on developing targeted therapies for cancer, particularly non-small cell lung cancer (NSCLC), utilizing advanced biotechnological and AI-driven processes. J INTS BIO Co.

, Ltd. specializes in the development of innovative therapies for cancer. Founded in 2020 in Seoul, South Korea, the company has completed two significant deals. Its most recent funding round, a Series C, raised KRW 18 billion on March 25, 2026, contributing to a total amount raised of KRW 36 billion and a current valuation of KRW 110 billion.

The founder's details and any previous ventures are not publicly available. JINTS BIO specializes in the development of innovative targeted therapies for non-small cell lung cancer (NSCLC) and other solid tumors, leveraging advanced biotechnological platforms and AI-driven drug development processes. Their primary product, JIN-A02, is a next-generation treatment designed to overcome resistance in NSCLC, validated through peer-reviewed studies published in Clinical Cancer Research. The company engages in collaborative research efforts, including partnerships with institutions like MD Anderson, enhancing its product offerings and scientific capabilities.

JINTS BIO targets a global market, focusing on areas with high incidences of lung cancer and advanced healthcare infrastructures, including North America, Europe, and specific emerging markets. JINTS BIO's revenue generation is closely tied to its success in bringing innovative cancer therapies to market and partnering with pharmaceutical firms for technology licensing and development collaboration. The company's business model involves direct transactions with healthcare providers and institutions, enabling the distribution of their flagship products. Revenue is generated from the sales of their proprietary drugs, milestone payments from partnerships, and royalties from licensed technologies, fostering a diversified revenue stream.

In the most recent year, 2025, JINTS BIO reported a revenue of KRW 1,681,939. 80. J INTS BIO Co. , Ltd.

plans to leverage its latest Series C funding of KRW 18 billion to expedite the development and launch of upcoming products, particularly enhancement of JIN-A02 and other therapies targeting various solid tumors. The company aims to expand its market presence in North America and Europe, targeting specific emerging markets by 2027. The recent funding will support these initiatives, allowing for increased research and development activities and strengthening strategic partnerships.